AFF4
AF4/FMR2 family member 4
Protein Summary
Key component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. In the SEC complex, AFF4 acts as a central scaffold that recruits other factors through direct interactions with ELL proteins (ELL, ELL2 or ELL3) and the P-TEFb complex. In case of infection by HIV-1 virus, the SEC complex is recruited by the viral Tat protein to stimulate viral gene expression. The protein encoded by this gene belongs to the AF4 family of transcription factors involved in leukemia. It is a component of the positive transcription elongation factor b (P-TEFb) complex. A chromosomal translocation involving this gene and MLL gene on chromosome 11 is found in infant acute lymphoblastic leukemia with ins(5;11)(q31;q31q23). [provided by RefSeq, Oct 2011]
- ENST00000265343
- ENSP00000265343
- ENSG00000072364
- ENST00000378595
- ENSP00000367858
- AF5Q31
- MCEF
- MCEF
- CHOPS
- AF5Q31
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
drug perturbation | 0.99 | ||
transcription factor binding site profile | 0.87 | ||
transcription factor perturbation | 0.84 | ||
cell type or tissue | 0.77 | ||
microRNA | 0.77 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 67.94 (req: < 5)
Gene RIFs: 22 (req: <= 3)
Antibodies: 228 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 67.94 (req: >= 5)
Gene RIFs: 22 (req: > 3)
Antibodies: 228 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0